Treatment of Early Rheumatoid Arthritis in a Multinational Inception Cohort of Latin American Patients The GLADAR Experience

Simple item page
dc.contributor.authorCardiel, Mario H.
dc.contributor.authorPons Estel, Bernardo A.
dc.contributor.authorSacnun, Monica P.
dc.contributor.authorWojdyla, Daniel
dc.contributor.authorSaurit, Veronica
dc.contributor.authorCarlos Marcos, Juan
dc.contributor.authorPinto, Maria Raquel C.
dc.contributor.authorCordeiro de Azevedo, Ana Beatriz
dc.contributor.authorda Silveira, Ines Guimaraes
dc.contributor.authorRadominski, Sebastiao C.
dc.contributor.authorXimenes, Antonio C.
dc.contributor.authorMassardo, Loreto
dc.contributor.authorBallesteros, Francisco
dc.contributor.authorRojas Villarraga, Adriana
dc.contributor.authorValle Onate, Rafael
dc.contributor.authorPortela Hernandez, Margarita
dc.contributor.authorEsquivel Valerio, Jorge A.
dc.contributor.authorGarcia De la Torre, Ignacio
dc.contributor.authorKhoury, Vianna J.
dc.contributor.authorMillan, Alberto
dc.contributor.authorRoberto Soriano, Enrique
dc.contributor.authorGLADAR
dc.date.accessioned2024-01-10T12:10:21Z
dc.date.available2024-01-10T12:10:21Z
dc.date.issued2012
dc.description.abstractBackground: Treatment of rheumatoid arthritis (RA) has evolved dramatically in the last decade. However, little is known about the way rheumatologists in Latin America treat their patients in clinical practice, outside the scope of clinical trials.
dc.description.abstractObjective: The objective of this study was to describe treatment patterns at disease onset in early RA with data from a large, multicenter, multinational inception cohort of Latin American patients.
dc.description.abstractMethods: Consecutive patients with early RA (<1 year of disease duration as diagnosed by a rheumatologist) from 46 centers in 14 Latin American countries were enrolled in the study. Clinical data, laboratory assessments, and a detailed registry on type of prescriptions were collected at baseline and at 3, 6, 12, 18, and 24 months of follow-up. Hands and feet x-rays were obtained at baseline and at 12 and 24 months. All data were captured in Arthros 6.1 database. Continuous variables were expressed as means and SDs, and categorical variables were expressed as percentages and 95% confidence intervals (95% CIs). Only therapeutic data at baseline are presented, corresponding to the period between disease onset and second visit (3 months).
dc.description.abstractResults: A total of 1093 patients were included. Eighty-five percent were female, and 76% had a positive rheumatoid factor. Mean age at diagnosis was 46.5 (SD, 14.2) years, and mean disease duration at the first visit was 5.8 (SD, 3.8) months. Between baseline and second visit (3 months), 75% of patients (95% CI, 72%-78%) received disease-modifying antirheumatic drugs. Methotrexate (MTX) alone or in combination was the most frequently used (60.5%), followed by antimalarials (chloroquine or hydroxychloroquine, 32.1%), sulfasalazine (7.1%), and leflunomide (LEF, 4%). In 474 patients (43%), initiation of disease-modifying antirheumatic drugs was within the first month after the first visit. In addition, 290 patients (26%; 95% CI, 23%-29%) received combination therapy as initial treatment. The most frequently used combinations were MTX + chloroquine (45%), MTX + hydroxychloroquine (25%), and MTX + sulfasalazine (16%). Eleven patients (1%; 95% CI, 0.5%-1.8%) received biologics. Sixty-four percent (95% CI, 60%-66%) received corticosteroids. Of those, 80% (95% CI, 77%-84%) received 10 mg of oral prednisone or less.
dc.description.abstractConclusions: In this cohort of Latin American patients with early RA, most patients received MTX very early in their disease course. Combination therapy was used approximately in 1 of every 4 patients as initial therapy. Biologics were rarely used at this early stage, and low-dose prednisone was commonly used.
dc.description.funderAbbott Laboratories
dc.description.funderAbbott
dc.fechaingreso.objetodigital2024-05-23
dc.format.extent9 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1097/RHU.0b013e31826d6610
dc.identifier.eissn1536-7355
dc.identifier.issn1076-1608
dc.identifier.pubmedidMEDLINE:23047532
dc.identifier.urihttps://doi.org/10.1097/RHU.0b013e31826d6610
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76570
dc.identifier.wosidWOS:000309963800002
dc.information.autorucMedicina;Massardo L ;S/I;100068
dc.issue.numero7
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final335
dc.pagina.inicio327
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.revistaJCR-JOURNAL OF CLINICAL RHEUMATOLOGY
dc.rightsacceso restringido
dc.subjecttreatment
dc.subjectrheumatoid arthritis
dc.subjectcorticosteroids
dc.subjectdisease-modifying antirheumatic drugs
dc.subjectMODIFYING ANTIRHEUMATIC DRUGS
dc.subjectFOLLOW-UP
dc.subjectRADIOGRAPHIC PROGRESSION
dc.subjectPRESCRIPTION PRACTICE
dc.subjectMETHOTREXATE
dc.subjectCRITERIA
dc.subjectTHERAPY
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleTreatment of Early Rheumatoid Arthritis in a Multinational Inception Cohort of Latin American Patients The GLADAR Experience
dc.typeartículo
dc.volumen18
sipa.codpersvinculados100068
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients - The GLADAR experience.pdf
Size:
3.81 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas